Hairpin mRNA elements and methods for the regulation of protein translation
View Patent ↗The present invention provides novel mRNA elements capable of forming hairpin, double-stranded RNA structures independent of other non-coding RNAs. These mRNAs are stably expressed, lack polyadenylation tails, and allow minimal protein translation except when in the presence of specific proteins. Also provided, are compositions and kits comprising the mRNA element, as well as methods for its use in the regulation of protein translation. Advantageously, the disclosed elements represent a novel tool useful in regulating the expression of a wide variety of proteins of interest.
1. A recombinant adeno-associated viral (rAAV) vector comprising at least a first expression cassette that comprises a promoter operably linked to at least a first nucleic acid segment that encodes at least a first mammalian polypeptide, wherein the first expression cassette lacks a polyA signal sequence, and wherein the mRNA produced from the vector lacks a polyA sequence at its 3′-end, but includes an inverted terminal repeat (ITR) at its 3′-end.
2. The rAAV vector of claim 1 , wherein the 3′-end of the mRNA further comprises a stable RNA element capable of forming a stable, hairpin, double-stranded RNA structure that regulates transcription of the mRNA, its translocation across a mammalian cell membrane, its translation into mature polypeptide, or a combination thereof.
3. A composition comprising the rAAV vector of claim 2 , wherein-the composition also comprises one or more endogenous or exogenously-provided cellular proteins, regulatory elements, siRNAs, helper plasmids, or any combination thereof, wherein the cellular proteins mediate the regulation of translation of the mRNA produced from the vector.
4. A composition comprising the rAAV vector of claim 3 , wherein the composition further comprises one or more endogenous or exogenously-provided cellular proteins, regulatory elements, siRNAs, helper plasmids, or any combination thereof that regulate translocation of the vector across a mammalian cell membrane.
5. A composition comprising the rAAV vector of claim 3 , wherein the one or more endogenous or exogenously-provided cellular proteins is Rep78/68.
6. The rAAV vector of claim 1 , further comprising a reporter gene, such as that encoding GFP.
7. A composition comprising the rAAV vector of claim 1 , wherein the composition comprises a helper plasmid that encodes one or more cellular or viral proteins, or a combination thereof that regulates expression of at least a first encoded mammalian polypeptide.
8. The rAAV vector of claim 1 , wherein the promoter is an inducible promoter.
9. The rAAV vector of claim 1 , wherein the vector is a self-complementary rAAV (scAAV).
10. The rAAV vector according to claim 1 , further comprising at least a first enhancer operably linked to the at least a first nucleic segment.
11. The rAAV vector according to claim 1 , further comprising at least a first mammalian intron sequence operably linked to the at least a first nucleic segment.
12. The rAAV vector according to claim 1 , wherein the at least a first mammalian polypeptide is of human, non-human primate, murine, feline, canine, porcine, ovine, bovine, equine, epine, caprine, or lupine origin.
13. The rAAV vector according to claim 1 , wherein the at least a first nucleic acid segment encodes a biologically-active human polypeptide.
14. The rAAV vector according to claim 1 , comprised within an infectious adeno-associated viral particle, virion, or a plurality of infectious AAV particles.
15. The recombinant adeno-associated viral (rAAV) vector of claim 1 , wherein a detectable level of transgene expression is observed from the vector.
16. The recombinant adeno-associated viral (rAAV) vector of claim 1 , wherein the vector undergoes complete gene expression, genome replication, encapsidation and progeny virion production.
17. A virion or an infectious viral particle comprising the rAAV vector in accordance with claim 1 .
18. The virion or an infectious viral particle of claim 17 , wherein the virion or infectious viral particle is a recombinant adeno-associated virus serotype 1 (rAAV1), a recombinant adeno-associated virus serotype 2 (rAAV2), recombinant adeno-associated virus serotype 3 (rAAV3), a recombinant adeno-associated virus serotype 4 (rAAV4), a recombinant adeno-associated virus serotype 5 (rAAV5), a recombinant adeno-associated virus serotype 6 (rAAV6), a recombinant adeno-associated virus serotype 7 (rAAV7), a recombinant adeno-associated virus serotype 8 (rAAV8), a recombinant adeno-associated virus serotype 9 (rAAV9), a recombinant adeno-associated virus serotype 10 (rAAV10), a recombinant adeno-associated virus serotype 11 (rAAV11), or a recombinant adeno-associated virus serotype 12 (rAAV12).
19. An isolated mammalian host cell comprising:
(a) the rAAV vector in accordance with claim 1 ;
(b) a virion or infectious viral particle comprising the rAAV vector in accordance with (a); or
(c) a plurality of infectious viral particles prepared from the rAAV vector in accordance with (a).
20. The isolated mammalian host cell according to claim 19 , wherein the cell is a human host cell.
21. A composition comprising:
(1) (a) the rAAV vector in accordance with claim 1 ;
(b) a virion or infectious viral particle comprising the rAAV vector in accordance with (a); or
(c) a plurality of infectious viral particles prepared from the rAAV vector in accordance with (a); and
(2) a pharmaceutically-acceptable buffer, carrier, vehicle, or diluent.
22. The composition according to claim 21 , further comprising a lipid, a liposome, a lipid complex, an ethosome, a niosome, a nanoparticle, a microparticle, a liposphere, a nanocapsule, or any combination thereof.
23. A kit comprising:
(1) a component selected from the group consisting of:
(a) the rAAV vector in accordance with claim 1 ;
(b) a virion or infectious viral particle comprising the rAAV vector in accordance with (a); or
(c) a plurality of infectious viral particles prepared from the rAAV vector in accordance with (a); and
(2) instructions for using the component in the diagnosis, prevention, treatment, or amelioration of one or more symptoms of a dystrophy, disease, disorder, abnormal condition, or a protein deficiency in a human.